Literature DB >> 26880474

Gastrointestinal cancer: CDX2: prognostic marker for high-risk colon cancer.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26880474     DOI： 10.1038/nrclinonc.2016.18

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Authors:  Piero Dalerba; Debashis Sahoo; Soonmyung Paik; Xiangqian Guo; Greg Yothers; Nan Song; Nate Wilcox-Fogel; Erna Forgó; Pradeep S Rajendran; Stephen P Miranda; Shigeo Hisamori; Jacqueline Hutchison; Tomer Kalisky; Dalong Qian; Norman Wolmark; George A Fisher; Matt van de Rijn; Michael F Clarke
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245
  1 in total
  3 in total

1.  CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.

Authors:  Fernando Alarid-Escudero; Deborah Schrag; Karen M Kuntz
Journal:  Value Health       Date:  2021-11-02       Impact factor: 5.725

2.  Homeobox protein CDX2 as a prognostic biomarker in solid malignancies: a meta-analysis.

Authors:  Jingsheng Yuan; Zhijie Yin; Kaixiong Tao; Guobing Wang; Jinbo Gao
Journal:  Oncotarget       Date:  2017-09-11

3.  Development of a prognostic signature for bladder cancer based on immune-related genes.

Authors:  Ying-Rui Shi; Kun Xiong; Xu Ye; Pei Yang; Zheng Wu; Xiong-Bing Zu
Journal:  Ann Transl Med       Date:  2020-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.